a Department of Urology, Yamagata University Faculty of Medicine, 2-2-2 Iida-nishi, Yamagata, Japan b Department of Pathology, Yamagata University Faculty of Medicine, 2-2-2 Iida-nishi, Yamagata, Japan
. [J]. Asian Journal of Urology, 2023, 10(3): 376-378.
Keisuke Funajima,Sei Naito,Takanobu Kabasawa,Hayato Nishida,Tomoyuki Kato,Mitsuru Futakuchi,Norihiko Tsuchiya. A durable complete response resulting from treatment with nivolumab plus ipilimumab for metastatic collecting duct carcinoma of the kidney. Asian Journal of Urology, 2023, 10(3): 376-378.
Procopio G, Verzoni E, Iacovelli R, Colecchia M, Torelli T, Mariani L. Is there a role for targeted therapies in the collecting ducts of Bellini carcinoma? Efficacy data from a retrospective analysis of 7 cases. Clin Exp Nephrol 2012; 16:464-7.
doi: 10.1007/s10157-012-0589-3
pmid: 22278601
[2]
Albadine R, Schultz L, Illei P, Ertoy D, Hicks J, Sharma R, et al. PAX8 (+)/p63 (-) immunostaining pattern in renal collecting duct carcinoma (CDC): a useful immunoprofile in the differential diagnosis of CDC versus urothelial carcinoma of upper urinary tract. Am J Surg Pathol 2010;34:965-9.
[3]
Dano D, Delteil C, Boissier R, Delaporte V, Habert P, Salas S, et al. Rechallenge of carboplatin-gemcitabine based chemotherapy for rapidly progressing metastatic collecting duct carcinoma of the kidney leading to a delayed and durable complete response: a case report. Oncol Lett 2019; 17: 3576-80.
[4]
Barrascout E, Beuselinck B, Ayllon J, B?ttig B, Moch H, Teghom C, et al. Complete remission of pulmonary metastases of Bellini duct carcinoma with cisplatin, gemcitabine and bevacizumab. Am J Case Rep 2012; 13:1-2.
doi: 10.12659/AJCR.882234
[5]
Oudard S, Banu E, Vieillefond A, Fournier L, Priou F, Medioni J, et al. Prospective multicenter phase II study of gemcitabine plus platinum salt for metastatic collecting duct carcinoma: results of a GETUG (Groupe d’Etudes des Tumeurs Uro-Génitales) study. J Urol 2007; 177:1698-702.
[6]
Pécuchet N, Bigot F, Gachet J, Massard C, Albiges L, Teghom C, et al. Triple combination of bevacizumab, gemcitabine and platinum salt in metastatic collecting duct carcinoma. Ann Oncol 2013; 24:2963-7.
doi: 10.1093/annonc/mdt423
pmid: 24190963
[7]
Watanabe K, Sugiyama T, Otsuka A, Miyake H. Complete response to combination therapy with nivolumab and ipilimumab for metastatic collecting duct carcinoma of the kidney. Int Cancer Conf J 2020; 9:32-5.
[8]
Yasuoka S, Hamasaki T, Kuribayashi E, Nagasawa M, Kawaguchi T, Nagashima Y, et al. Nivolumab therapy for metastatic collecting duct carcinoma after nephrectomy: a case report. Medicine 2018; 97:e13173. https://doi.org/10.1097/MD.0000000000013173.
[9]
Mizutani K, Horie K, Nagai S, Tsuchiya T, Saigo C, Kobayashi K, et al. Response to nivolumab in metastatic collecting duct carcinoma expressing PD-L1:a case report. Mol Clin Oncol 2017; 7:988-90.
[10]
Malouf GG, Compérat E, Yao H, Mouawad R, Lindner V, Riouxleclercq N, et al. Unique transcriptomic profile of collecting duct carcinomas relative to upper tract urothelial carcinomas and other kidney carcinomas. Sci Rep 2016; 6:30988. https://doi.org/10.1038/srep30988.
doi: 10.1038/srep30988
pmid: 27484008
[11]
Arbour KC, Mezquita L, Long N, Rizvi H, Auclin E, Ni A, et al. Impact of Baseline steroids on efficacy of programmed cell death-1 and programmed death-ligand 1 blockade in patients with non-small-cell lung cancer. J Clin Oncol 2018;36: 2872-8.
[12]
Nikolaou V, Sibaud V, Fattore D, Sollena P, Ortiz-Brugués A, Giacchero D, et al. Immune checkpoint-mediated psoriasis: a multicenter European study of 115 patients from the European Network for Cutaneous Adverse Event to Oncologic Drugs (ENCADO) group. J Am Acad Dermatol 2021;84:1310-20.
